GM
Geoff Meacham B of A Securities Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
51
Inovio Pharmaceuticals
INO
$146M
| $2.75 | $24 |
773%
upside
| Underperform |
1 Nov ‘22
2 years ago |
|
52
Eli Lilly
LLY
$673B
| $750.61 | $355 |
53%
downside
| Overweight |
7 Jul ‘22
3 years ago |
|
53
Omeros
OMER
$290M
| $4.26 | $4 |
6%
downside
| Neutral |
8 Jun ‘22
3 years ago |
|
54
Kiniksa Pharmaceuticals
KNSA
$2.73B
| $36.86 | $34 |
8%
downside
| Buy |
29 Dec ‘21
3 years ago |
|
55
Erasca
ERAS
$457M
| $1.61 | $28 |
1,639%
upside
| Buy |
10 Aug ‘21
4 years ago |
|
56
Century Therapeutics
IPSC
$43.4M
| $0.5029 | $34 |
6,661%
upside
| Buy |
13 Jul ‘21
4 years ago |
|
57
Y-mAbs Therapeutics
YMAB
$390M
| $8.58 | $56 |
553%
upside
| Buy |
7 May ‘21
4 years ago |
|
58
Esperion Therapeutics
ESPR
$512M
| $2.54 | $35 |
1,278%
upside
| Neutral |
15 Jan ‘21
4 years ago |
|
59
Galecto
GLTO
$3.42M
| $2.58 | $525 |
20,249%
upside
| Buy |
23 Nov ‘20
4 years ago |
|
60
PMV Pharmaceuticals
PMVP
$84.8M
| $1.60 | $42 |
2,525%
upside
| Buy |
20 Oct ‘20
4 years ago |
|
61
MeiraGTx Holdings
MGTX
$615M
| $7.65 | $20 |
161%
upside
| Buy |
15 Sep ‘20
5 years ago |
|
62
Sangamo Therapeutics
SGMO
$157M
| $0.5197 | $20 |
3,748%
upside
| Buy |
8 Sep ‘20
5 years ago |
|
63
Puma Biotechnology
PBYI
$237M
| $4.71 | $9 |
91%
upside
| Underperform |
25 Jun ‘20
5 years ago |
|
64
Regenxbio
RGNX
$500M
| $9.89 | $60 |
507%
upside
| Buy |
25 Jun ‘20
5 years ago |
|
|
GNFT
65
Genfit
GNFT
$214M
| $4.27 | $7 |
64%
upside
| Underperform |
25 Jun ‘20
5 years ago |
|
66
Coherent
COHR
$15.5B
| $99.22 | $31 |
69%
downside
| Overweight |
23 Mar ‘20
5 years ago |
|
67
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $19 |
12%
downside
| Equal-Weight |
25 Feb ‘20
5 years ago |
|